Sign In
Buy IOVA
$3.79
-0.310 (-7.56%)
At Close: Jun 03, 2026
Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why
02:56pm, Monday, 08'th Apr 2024
Iovance (IOVA) surges on the recent FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.
Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics
05:03am, Friday, 05'th Apr 2024
Both of these companies recently won regulatory approval for their first products. Both Iovance Biotherapeutics and CRISPR Therapeutics have developed game-changing treatment technologies.
2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street
04:11am, Tuesday, 26'th Mar 2024
The Nasdaq Composite index is up sharply over the past year, but it contains at least two growth stocks poised to run even higher. Investment bank analysts who follow Viking Therapeutics think the sto
7 Biotech Stocks Ready to Ride the Sector's Resurgence
08:01pm, Monday, 18'th Mar 2024
Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.
Iovance Biotherapeutics Stock Has 22% Upside, According to 1 Wall Street Analyst
04:42am, Wednesday, 06'th Mar 2024
Iovance Biotherapeutics is commercializing its first therapy. The product will be fairly expensive to manufacture and distribute.
FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study
02:01pm, Tuesday, 05'th Mar 2024
The FDA removes the clinical hold on Iovance's (IOVA) mid-stage study on LN-145 in certain NSCLC patients after reviewing the company's proposal for additional safety measures and monitoring.
Could Iovance Biotherapeutics Stock Help You Become a Millionaire?
06:50am, Saturday, 02'nd Mar 2024
Iovance Biotherapetics recently obtained its first approval from the Food and Drug Administration. The company now has a potential blockbuster on its hands.
Could Iovance Biotherapeutics Stock Help You Become a Millionaire?
06:50am, Saturday, 02'nd Mar 2024
Iovance Biotherapetics recently obtained its first approval from the Food and Drug Administration. The company now has a potential blockbuster on its hands.
Iovance Biotherapeutics to Present at Upcoming Conferences
05:00pm, Friday, 01'st Mar 2024
SAN CARLOS, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor in
Why Iovance Biotherapeutics Stock Got Trounced on Thursday
05:47pm, Thursday, 29'th Feb 2024
The biotech published its first set of quarterly results after winning an important regulatory nod. Its revenue for the period fell notably short of pundit expectations, however.
Iovance's (IOVA) Q4 Earnings & Sales Fall Short of Estimates
11:41am, Thursday, 29'th Feb 2024
Iovance (IOVA) reports dismal earnings in the fourth quarter. Management is in the process of commercially launching the recently approved melanoma drug Amtagvi in the United States.
Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Misses Revenue Estimates
06:36pm, Wednesday, 28'th Feb 2024
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.64 per share a year ago.
Why Iovance (IOVA) Might Surprise This Earnings Season
09:56am, Tuesday, 27'th Feb 2024
Iovance (IOVA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
1 Soaring Growth Stock That Could Rise Another 53%, According to Wall Street
05:39am, Monday, 26'th Feb 2024
Iovance Biotherapeutics earned approval for its first new drug, Amtagvi, on Feb. 16. Amtagvi is a first-in-class treatment that uses a patient's own immune cells to attack solid tumors.
Is Iovance a Buy After Its First Regulatory Win?
05:01am, Sunday, 25'th Feb 2024
Iovance shares have surged more than 70% in just a few days. The gains came after the biotech won approval for its very first product, one that relies on the body's own cells.
